Core Viewpoint - The company, Tuoxin Pharmaceutical (301089.SZ), announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received two GMP compliance inspection notices from the Henan Provincial Drug Administration, indicating that its production facilities meet the required quality management standards for drug production [1]. Group 1: GMP Compliance - Xinxiang Pharmaceutical's facilities for the active pharmaceutical ingredients (APIs) Olaparib (an anti-tumor drug) and Cytidine Diphosphate Choline have passed the GMP compliance inspection [1]. - The approval allows the API Cytidine Diphosphate Choline to be marketed immediately, while Olaparib will be available for sale after filing with the National Medical Products Administration due to a change of address [1]. Group 2: Business Implications - The successful GMP compliance will enhance the company's ability to ensure product quality stability and production supply capacity [1]. - This development is expected to better meet market demand for the relevant drugs and significantly promote the company's future business expansion [1].
拓新药业：子公司收到药品GMP符合性检查告知书